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he cellular pathways required for herpes simplex
virus (HSV) invasion have not been deﬁned. To test
the hypothesis that HSV entry triggers activation of
Ca
 
2
 
 
 
-signaling pathways, the effects on intracellular calcium
concentration ([Ca
 
2
 
 
 
]
 
i
 
) after exposure of cells to HSV
were examined. Exposure to virus results in a rapid and
transient increase in [Ca
 
2
 
 
 
]
 
i
 
. Pretreatment of cells with
pharmacological agents that block release of inositol 1,4,5-
triphosphate (IP
 
3
 
)–sensitive endoplasmic reticulum stores
abrogates the response. Moreover, treatment of cells with
T
 
these pharmacological agents inhibits HSV infection and
prevents focal adhesion kinase (FAK) phosphorylation,
which occurs within 5 min after viral infection. Viruses
deleted in glycoprotein L or glycoprotein D, which bind but
do not penetrate, fail to induce a [Ca
 
2
 
 
 
]
 
i
 
 response or trigger
FAK phosphorylation. Together, these results support a model
for HSV infection that requires activation of IP
 
3
 
-responsive
Ca
 
2
 
 
 
-signaling pathways and that is associated with FAK
phosphorylation. Deﬁning the pathway of viral invasion
may lead to new targets for anti-viral therapy.
 
Introduction
 
Invasion of cells by herpes simplex virus type 1 or type 2
(HSV-1 and HSV-2) requires binding of the envelope glyco-
protein C (gC) and/or glycoprotein B (gB) to heparan sulfate
receptors, engagement by glycoprotein D (gD) of one of
several coreceptors (herpes virus entry mediators), fusion of
the viral envelope with the cell plasma membrane, and delivery
of the viral capsid into the cell cytoplasm (Morgan et al.,
1968; Herold et al., 1991, 1994; Spear et al., 2000; Spear
and Longnecker, 2003). Most reports have focused on iden-
tifying the receptors and ligands required for viral binding
and entry. However, the cellular pathways that participate in
this process have not been defined. Knowledge of these
pathways may facilitate development of novel strategies to
prevent infection.
For most cell types, HSV entry (defined as fusion of the
viral envelope with the cell plasma membrane and delivery
of the viral capsid into the cell cytoplasm) is resistant to
agents such as amantadine, chloroquine, and trifluoperazine,
whose actions are known to alter endocytic pathways
(Wittels and Spear, 1991; Nicola et al., 2003). Fusion requires
the concerted action of gD, oligomers of gB, and hetero-
dimers of glycoproteins H and L (gH–gL; Spear and
Longnecker, 2003). Cells transiently or permanently express-
ing gD, gB, and gH–gL (Turner et al., 1998; Muggeridge,
2000) can induce fusion. Deletion of any one of these glyco-
proteins results in loss of penetration (Cai et al., 1987;
Johnson and Ligas, 1988; Ligas and Johnson, 1988; Forrester
et al., 1992; Hutchinson et al., 1992). However, the mech-
anism by which interactions between these viral glycopro-
teins and the cell surface trigger fusion is not defined. No
specific fusion domains in HSV envelope glycoproteins
have been identified.
We observed that HSV entry is associated with tyrosine
phosphorylation of cellular proteins (Qie et al., 1999). Using
immunoprecipitation and Western blotting, we found that
several host cell proteins become tyrosine phosphorylated
within 5–10 min after exposure to either HSV-1 or HSV-2.
However, no phosphorylation was detected when cells were
exposed to a virus deleted in gL that binds but fails to
penetrate. Phosphorylation was restored when the gL deletion
virus was grown on complementing gL-expressing cells. Viral
infection and gene expression were inhibited by tyrphostin
B46, a protein tyrosine kinase inhibitor that prevents the
phosphorylation of cellular proteins (Qie et al., 1999).
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These analyses suggest that phosphorylation pathways are
activated in response to initiation of fusion and may be re-
quired for infection.
Several reports have demonstrated that phosphorylation
may occur in conjunction with Ca
 
2
 
 
 
 signaling (Sayeski, et al.,
2000; Trinkaus-Randall et al., 2000). The ER is the main
storage site for intracellular Ca
 
2
 
 
 
, and mobilization of Ca
 
2
 
 
 
from this store is an essential triggering signal for downstream
events, including activation of phosphorylation pathways.
Moreover, increases in intracellular calcium concentration
([Ca
 
2
 
 
 
]
 
i
 
) have been associated with membrane fusion for a
variety of biological membranes, including some enveloped
viruses. For example, binding of HIV-1 gp120 to CD4 and
engagement of chemokine coreceptors results in activation of
Ca
 
2
 
 
 
-signaling pathways (Davis et al., 1997; Alfano et al.,
1999; Liu et al., 2000). Ca
 
2
 
 
 
 signaling also may play a role in
human cytomegalovirus (HCMV) entry (Keay et al., 1995).
Specifically, exposure of human fibroblasts to HCMV medi-
ates an increase in inositol-1,4,5-triphosphate (IP
 
3
 
), leading
to mobilization of internal Ca
 
2
 
 
 
 stores. We hypothesize that
exposure to HSV might also activate the IP
 
3
 
 pathway leading
to an increase in [Ca
 
2
 
 
 
]
 
i
 
, which, in turn, may activate phos-
phorylation pathways. Activation of these signaling pathways
may facilitate viral penetration and/or the transport of in-
coming viral capsids to the nucleus.
We tested this hypothesis for HSV-1 and HSV-2 using
two different epithelial cell lines. Although the two serotypes
are similar in many respects, differences in epidemiology,
cell tropism, and spectrum of clinical disease are well
known. For example, HSV-1 commonly infects oral mu-
cosa, whereas HSV-2 preferentially infects genital mucosa.
With respect to viral entry, serotype differences in the rela-
tive contribution of gC and gB toward heparan sulfate bind-
ing and in use of gD coreceptors have been described previ-
ously (Herold et al., 1991, 1994; Spear et al., 2000). Thus,
we explored the role of Ca
 
2
 
 
 
-signaling pathways in viral in-
fection for both serotypes.
 
Results
 
Exposure of epithelial cells to HSV induces rapid 
increase in [Ca
 
2
 
 
 
]
 
i
 
To evaluate whether HSV infection is associated with activa-
tion of Ca
 
2
 
 
 
-signaling pathways, the effects on [Ca
 
2
 
 
 
]
 
i
 
 of ex-
posure of cells to HSV were examined. Vero cells were
loaded with Fura-2 and then exposed sequentially to PBS
buffer or HSV at a multiplicity of infection (moi) of 5
plaque-forming units (pfu)/cell. Experiments were con-
ducted with wild-type virus or deletion mutants harvested
from complementing cells. The complemented viruses be-
have like wild-type virus with respect to binding and entry
(Johnson and Ligas, 1988; Ligas and Johnson, 1988; Roop
et al., 1993; Novotny et al., 1996), and have been used in re-
ports of viral entry (Montgomery et al., 1996). An acute in-
crease in superfusate flow rate of PBS alone, simulating the
rapid addition of virus to the bathing medium, had no effect
on resting [Ca
 
2
 
 
 
]
 
i
 
 (unpublished data). In contrast, exposure
to HSV-1 results in a rapid increase in [Ca
 
2
 
 
 
]
 
i
 
, which peaks
within one minute, followed by a lower amplitude shoulder
and then a return to baseline within 1 min (Fig. 1, bottom
left). Similar results were obtained using human cervical epi-
thelial cells (CaSki; Fig. 1, bottom right), although the
shoulder was more pronounced and the response persisted
for 
 
 
 
3 min before returning to baseline. The mean change
(
 
 
 
) in peak [Ca
 
2
 
 
 
]
 
i
 
 obtained for HSV-1 on Vero cells, HSV-1
on CaSki cells, or HSV-2 on CaSki cells was 247.5 
 
 
 
 157
nM, 
 
n
 
 
 
 
 
 25; 354.5 
 
 
 
 178, 
 
n
 
 
 
 
 
 8; and 443 
 
 
 
 219, 
 
n
 
 
 
 
 
 5,
respectively (not significant; ANOVA; Fig. 2 A).
 
ER and extracellular Ca
 
2
 
 
 
 stores contribute to this 
viral-induced [Ca
 
2
 
 
 
]
 
i
 
 transient
 
To determine whether release of ER stores and/or influx of
extracellular Ca
 
2
 
 
 
 mediate the response to HSV, the effects
of pharmacological inhibitors of each on the observed [Ca
 
2
 
 
 
]
 
i
 
transient were compared. Fura-2–loaded Vero cells were
Figure 1. The [Ca
2 ]i response to HSV. 
Vero or CaSki cells were loaded with the 
Ca
2  indicator dye Fura-2, exposed to 
HSV-1(KOS) (moi  1.0), and changes in 
[Ca
2 ]i were monitored. Representative 
fields from Vero cells as viewed under 
the microscope before (left) and  20 s 
after exposure to virus (right) are shown 
in the top panels, and the results from a 
single experiment for each cell type in 
which 5–7 individual cells were moni-
tored are shown graphically below.T
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treated with 100 
 
 
 
M 2-aminoethoxydiphenylborate (2-APB)
followed by exposure to HSV and [Ca
 
2
 
 
 
]
 
i
 
 response was mon-
itored. 2-APB, an IP
 
3
 
 receptor antagonist that prevents IP
 
3
 
-
mediated release of ER Ca
 
2
 
 
 
, essentially abolishes the Ca
 
2
 
 
 
response to HSV (Fig. 2 B). The 
 
 
 
 [Ca
 
2
 
 
 
]
 
i
 
 in response to
HSV-1 in Vero cells pretreated with 2-APB was 
 
 
 
57.1 
 
 
 
24.5 nM, 
 
n
 
 
 
 
 
 5 (Fig. 2, A and B; P 
 
 
 
 0.001, ANOVA). To
further examine the importance of ER Ca
 
2
 
 
 
 stores to the re-
sponse, Fura-2–loaded Vero cells were treated with 10 
 
 
 
M
thapsigargin (Tg), which induces the release of intracellular
ER Ca
 
2
 
 
 
 stores and prevents refilling by inhibition of the ER
Ca
 
2
 
 
 
-ATPase. Thus, Tg would abrogate the Ca
 
2
 
 
 
 response
to virus if it requires mobilization of ER stores (Thastrup et
al., 1990). Tg induced a modest increase in resting [Ca
 
2
 
 
 
]
 
i
 
(from 40 
 
 
 
 11 to 74 
 
 
 
 13 nM; 
 
n
 
 
 
 
 
 10, P 
 
 
 
 0.01), which
persists for 
 
 
 
3 min in Vero cells before returning to baseline
levels. Subsequent exposure to virus results in no further in-
crease in [Ca
 
2
 
 
 
]
 
i
 
 above baseline (
 
 
 
 [Ca
 
2
 
 
 
]
 
i
 
 0.89 
 
 
 
 5.7 nM,
 
n
 
 
 
 
 
 10; Fig. 2, A and C, P 
 
 
 
 0.001, ANOVA). Similar re-
sults were obtained with CaSki cells, except that Tg induced
a greater increase in resting [Ca
 
2
 
 
 
]
 
i
 
 (from 91 
 
 
 
 35 to 424 
 
 
 
119 nM; 
 
n
 
   6, P   0.01). Subsequent exposure to virus re-
Figure 2. Changes in [Ca
2 ]i in response to HSV-1 
or HSV-2 on CaSki cells and in response to HSV-1 
in Vero cells pretreated with pharmacological 
inhibitors. Means of at least three independent 
experiments in the absence or presence of each 
drug are depicted in the bar graph (A); error bars 
indicate SD and the asterisks denote P   0.001 by 
ANOVA (see text). Results are shown for individually 
monitored Vero cells after treatment with 100  M 
2-APB (B), 10  M Tg (C), 10  M verapamil (D), 
or 10  M nifedipine (E), and subsequent challenge 
with HSV-1(KOS) (F and G). Time-expanded tracings 
of cells pretreated with PBS alone or with verapamil 
are shown in F and G, respectively.T
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sulted in a minimal increase in [Ca
2 ]i above baseline ( 
[Ca
2 ]i 22   13 nM, n   6, P   0.001, ANOVA).
To explore the possibility that Ca
2  influx across voltage-op-
erated channels also contributes to the response to HSV, cells
were pretreated with 10- M concentrations of verapamil or
nifedipine. Minimal change in the amplitude of [Ca
2 ]i re-
sponse to virus was observed. The   [Ca
2 ]i in response
to HSV-1 in nifedipine- or verapamil-treated Vero cells was
163   65 (n   11) and 251   120 (n   12), respectively (Fig.
2, A, D, and E). However, the response to virus was modified
in cells treated with these agents as reflected in the loss of the
shoulder (Fig. 2, F and G). Similar results were obtained for
HSV-2 and with CaSki cells (unpublished data). Together,
these results suggest that the peak response to virus reflects re-
lease of ER Ca
2  stores, whereas the shoulder may represent in-
flux of Ca
2  across voltage-operated channels. The results ob-
tained are consistent with the notion that plasma membrane
Ca
2  channels may be linked to the IP3 receptors. Similar re-
sults have been described in several other systems (Berridge,
1995; Parekh and Penner, 1997; Uhlen et al., 2000; Bakowski
et al., 2001; Straube and Parekh, 2001; Valencia et al., 2001).
Effects of Ca
2  inhibitors on viral infection
To determine whether the Ca
2  response is important for vi-
ral infection, synchronized infectivity assays were conducted
Figure 3. The ER Ca
2  release is required for HSV infection. The 
effects of pretreating cells for 1 h with 50  M BAPTA-AM, 0.5 mM 
EGTA, or adding 100  M 2-APB, 10  M nifedipine, or 10  M 
verapamil during viral penetration on HSV-1(KOS), HSV-2(G), or 
VSV infection of Vero cells (top) or CaSki cells (bottom) were examined. 
Results are presented as pfu formed in the presence of the indicated 
concentration of drug as a percentage of pfu formed in cells treated 
with control buffer (5% DMSO for pharmacological inhibitors or 5% 
methanol for BAPTA), and are means of at least three independent 
experiments conducted in duplicate. Cytotoxicity of pharmacological 
agents was determined in parallel after a 2-h exposure to drug 
and quantifying viable, proliferating cells at 24 h by MTS assay. 
Cell viability results are expressed as odu reading in the presence 
of the drug as a percentage of odu reading in the presence of control 
buffer, and are means of two independent experiments conducted 
in triplicate. Asterisks denote P   0.001, ANOVA compared 
with controls.
Figure 4. 2-APB prevents VP16 nuclear transport and viral ICP4 
expression. Time-course experiments were conducted to determine 
the effects of pharmacological inhibitors of Ca
2  signaling on VP16 
transport to the nucleus and ICP4 expression after infection of CaSki 
cells with HSV-2(G). 10  M verapamil (V), 10  M nifedipine (N), or 
100  M 2-APB (A) were added during the 4 C binding period, at the 
time of temperature shift (penetration), or immediately after entry. 
Controls included cells treated with 5% DMSO. Nuclear extracts 
were prepared 4 h after infection for VP16 (top blot), and cell lysates 
were prepared 5 h after infection for ICP4 (middle blot). VP16 and 
ICP4 were detected by analyzing Western blots; lanes were loaded 
with extracts or lysates from equivalent cell numbers. The blots of 
cell lysates were also probed with mAb for  -actin to control for 
loading (bottom blot). The blots were scanned and the background 
from mock-infected cells was subtracted. (B) The odu for viral protein 
per odu for  -actin as a percentage of controls. Results are the
mean   SD obtained from three independent experiments.T
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in which 100  M 2-APB, 10  M nifedipine, or 10  M ve-
rapamil were added at the time of viral penetration for 1 h.
HSV attachment, which occurs at 4 C, can be differentiated
from penetration, which occurs after a shift to 37 C. The ef-
fects of these pharmacological agents on cell viability were
determined in parallel. Although Tg does not significantly
reduce cell viability at a concentration of 10  M, it is
known to have pleiotropic effects on cell function, including
inhibition of protein synthesis at concentrations as low as 30
nM (Soboloff and Berger, 2002), and for this reason, Tg was
not included. Results for Vero and CaSki cells are summa-
rized in Fig. 3. HSV-1 and HSV-2 but not vesicular stoma-
titis virus (VSV) infections were reduced after treatment of
cells with 2-APB (P   0.001, ANOVA). In contrast, the
Ca
2  channel blockers had little or no effect on viral infec-
tion (Fig. 3). These results suggest that release of IP3-sensi-
tive ER stores is required for HSV infection. To further as-
sess the importance of [Ca
2 ]i on HSV infection, the cells
were pretreated for 2 h with 50  M BAPTA-AM, a cell-per-
meable cytosolic Ca
2  chelator, or with 0.5 mM EGTA, a
concentration that chelates extracellular Ca
2  and thereby
prevents entrance of extracellular Ca
2  (Zwick et al., 1999,
Bouchard et al., 2001), and were then infected with virus.
Cell viability was monitored in parallel. Pretreatment of cells
with BAPTA-AM (but not EGTA) reduced HSV infection
to a similar extent as that observed with 2-APB (Fig. 3, P  
0.001, ANOVA).
To more specifically examine which steps in HSV infec-
tion require activation of the IP3 pathway, additional experi-
ments were conducted and infection was monitored by
examining transport of VP16, a viral tegument protein.
Detection of VP16 in the nucleus is one of the earliest mark-
ers of successful viral entry and transport. Synchronized in-
fectivity assays were conducted and the pharmacological
agents were added during binding (at 4 C for 2 h), penetra-
tion (at the time of temperature shift for 15 min), or for 1 h
immediately after penetration (post-citrate treatment). Con-
trols included cells treated with 5% DMSO. Nuclear ex-
tracts were prepared 4 h after infection and the nuclear
transport of VP16 was compared using Western blots. In
parallel, the expression of the viral immediate early gene
product, ICP4, was compared by preparing Western blots of
cell lysates 5 h after infection. The VP16 and ICP4 blots
were scanned, the background from mock infected lanes
subtracted, and the optical densitometry corrected for differ-
ences in loading (optical densitometry units [odu] for viral
protein per odu for  -actin). A representative blot for VP16
after infection of CaSki cells with HSV-2(G) is shown in
Fig. 4 A (top blot). VP16 transport to the nucleus is inhib-
ited if cells are treated with 2-APB, but not nifedipine or
verapamil. The inhibition is greatest when 2-APB is added
during penetration. Similarly, 2-APB, but not nifedipine or
verapamil, also reduces ICP4 expression (Fig. 4 A, middle
blot). Results from three independent experiments are sum-
marized graphically in Fig. 4 B. Similar results were ob-
tained using Vero cells and HSV-1 (unpublished data).
These results suggest that IP3-mediated Ca
2  signaling is re-
quired during penetration, and either facilitates the fusion
process and/or transport of incoming capsids and tegument
proteins to the nucleus.
Similar experiments were conducted using BAPTA-AM
and EGTA. Cells were pretreated for 2 h with the chelators,
infected with virus, and nuclear extracts or cell lysates were
prepared at 4 and 5 h after infection, respectively. Represen-
tative gels with CaSki cells and HSV-2 are shown in Fig. 5
A. Consistent with the results obtained with the pharmaco-
Figure 5. Effects of Ca
2  chelators on VP16 
transport and ICP4 expression. CaSki cells were 
pretreated with BAPTA-AM, EGTA, or 5% methanol 
in PBS (control) for 2 h, washed three times, and 
then exposed to HSV-2(G) and nuclear extracts or 
cell lysates prepared as described in Materials and 
methods. (A) Representative blots probed for VP16 
(top blot) or ICP4 (middle blot). Blots were also 
probed with mAb for  -actin to control for loading 
(bottom blot). The blots were scanned and the 
background from mock-infected cells was sub-
tracted. (B) The odu for viral protein per odu for 
 -actin as a percentage of control (HSV-2 in the 
absence of pharmacological inhibitor). Results are 
the mean   SD obtained from three independent 
experiments; asterisks indicate P   0.001 by 
ANOVA.T
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logical inhibitors, pretreatment of cells with the intracellular
(but not the extracellular) chelator reduced transport of
VP16 to the nucleus and expression of ICP4 by  60–70%
(Fig. 5 B; P   0.001, ANOVA). Similar results were ob-
tained with Vero cells and HSV-1. The inhibitory effects of
BAPTA-AM were concentration dependent, presumably re-
flecting low esterase activity in CaSki cells (hydrolysis of the
ester group by cellular esterases is required for chelation).
Inhibition of Ca
2  signaling also prevents 
phosphorylation of FAK
HSV entry is associated with tyrosine phosphorylation of
several cellular proteins within 5–10 min after infection (Qie
et al., 1999). We hypothesized that one of these proteins
may be FAK and that activation of FAK phosphorylation
pathways may be linked to the release of IP3-sensitive ER
Ca
2  stores. To explore this possibility, cells were serum
starved overnight and mock infected or exposed to HSV at
37 C. At various times after exposure, cell lysates were pre-
pared and examined for expression of phosphorylated and
total FAK by Western blotting. As shown in Fig. 6, HSV-2
induces a three- to fourfold increase in FAK phosphoryla-
tion within 5 min after exposure. Similar results were ob-
tained for Vero cells. To determine if the release of ER Ca
2 
is linked to the observed phosphorylation of FAK, syn-
chronized infection experiments were conducted in which
2-APB or nifedipine were added during viral binding or pene-
tration. FAK phosphorylation was examined 10 min after ci-
trate treatment (Fig. 7 A). Alternatively, cells were pretreated
with BAPTA-AM or EGTA for 2 h and then challenged
with virus (Fig. 7 B). Results from three independent exper-
iments are summarized in the graph (Fig. 7 C). Pretreatment
with 50  M BAPTA-AM and addition of 2-APB during vi-
ral penetration reduced the FAK phosphorylation (expressed
as percentage of total FAK) to levels similar to that observed
for mock-infected cells. In contrast, EGTA and nifedipine
had little or no effect. These findings suggest that FAK
phosphorylation may be linked to IP3 pathway activation
and release of internal [Ca
2 ]i stores. Alternatively, it may be
that viral entry itself, and not the release of internal [Ca
2 ]i,
promotes FAK phosphorylation.
Viral binding is not sufficient to induce Ca
2  signaling 
or FAK phosphorylation
For both HIV and HCMV, binding of viral glycoproteins to
the cell surface is sufficient to induce a Ca
2  response (Keay
et al., 1995; Keay and Baldwin, 1996; Alfano et al., 1999;
Liu et al., 2000). To determine if this is also the case for
Figure 6. HSV induces FAK phosphorylation within 5 min of 
exposure to virus. CaSki cells were serum starved overnight, 
exposed to HSV-2(G) or mock infected, and at the indicated times 
after infection, cell lysates were prepared and proteins were separated, 
transferred by Western blotting, and incubated with anti-FAK pY
397 
antibody. Blots were then stripped and reprobed with mAb to total 
FAK. Blots were scanned and the results are expressed as the in-
crease in levels of phosphorylated FAK as a percentage of total FAK 
compared with mock-infected cells. Results are the mean   SD ob-
tained from three independent experiments.
Figure 7. 2-APB and BAPTA-AM prevent viral-induced FAK 
phosphorylation. CaSki cells were serum starved overnight, and a 
synchronized infection with HSV-2(G) was conducted as described 
in Materials and methods. 100  M 2-APB, 10  M nifedipine, or 
control buffer (5% DMSO) was added to cells at the time of binding 
or penetration (temperature shift, 15 min, 37 C). Cells were treated 
with low pH citrate buffer, washed, and cell lysates were prepared 
10 min after citrate treatment. Western blots were prepared, probed 
with anti-FAK pY
397, and scanned by optical densitometry. Blots 
were then stripped and reprobed with mAb to total FAK. A represen-
tative blot is shown in A. Alternatively, cells were pretreated for 2 h 
with BAPTA-AM, EGTA, or 5% methanol in PBS (control), and then 
exposed to HSV-2(G). (B) Lysates were prepared 5 min after infection 
and analyzed by Western blotting for FAK phosphorylation. (C) Results 
obtained from three independent experiments are summarized 
graphically as odu of phosphorylated FAK:odu total FAK as a per-
centage of control (HSV-2(G) in the absence of any inhibitors). 
Results are the mean   SD obtained from three independent 
experiments; asterisks indicate P   0.001, ANOVA.T
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HSV, the effect of exposing cells to equivalent particle num-
bers of HSV-1(KOS) viruses deleted in gL or gD purified
from noncomplementing Vero cells (phenotypically deleted)
was compared with results obtained with virus purified from
complementing cells (phenotypically wild-type). Deletion of
gD or gL results in virions that bind, but fail to penetrate
(Ligas and Johnson, 1988; Roop et al., 1993). The relative
concentration of purified viral particles was determined by
comparing the odu of the gB or gD band after SDS-PAGE
and Western blotting, as described previously (Qie et al.,
1999; Cheshenko and Herold, 2002). As shown in Fig. 8,
there was little increase in [Ca
2 ]i after exposure of cells to
noncomplemented gD- or gL-deleted viruses (  [Ca
2 ]i  
9.6   23.6, n   11 and 73   16, n   5, respectively). The
Ca
2  response was restored when cells were exposed to the
complemented virus (  [Ca
2 ]i   218   156, n   11 and
276   82, n   5, respectively. These results suggests that
binding in the absence of either gD or gL is not sufficient to
induce changes in [Ca
2 ]i. An HSV-2(G) virus deleted in
gB-2, which is impaired both in binding and penetration,
also failed to induce a Ca
2  response (unpublished data).
To determine whether viral penetration is required to in-
duce FAK phosphorylation, the effects of exposing serum-
starved cells to equivalent particle numbers of the deletion
viruses purified from complementing or noncomplementing
cells or heat-inactivated (HI) virus were compared. Previous
reports have shown that treatment of virus for 1 h at 56 C is
similar to ultraviolet light inactivation with respect to entry
(Moriuchi et al., 2000). Moreover, in pilot experiments, we
found that HI virus enters as indicated by successful trans-
port of VP16 to the nucleus, but fails to express ICP4 (un-
published data). Cells were exposed to each of the purified
viral preparations and Western blots for phosphorylated
FAK and total FAK were prepared 10 min post exposure.
Representative gels are shown in Fig. 9. There was no in-
crease in FAK phosphorylation in cells exposed to virus de-
leted in gL, gD, or gB compared with mock-infected cells.
In contrast, a twofold increase in FAK phosphorylation was
observed if cells were exposed to virus purified from comple-
menting cell lines or to HI virus. Together, these results sug-
gest that the full complement of glycoproteins required for
penetration is required to induce signaling events.
Discussion
We have shown that release of IP3-sensitive Ca
2  stores held
within the ER facilitates HSV-1 and HSV-2 entry and/or
transport of incoming viral capsids to the nucleus. A possible
paradigm is depicted in Fig. 10. After interactions between
heparan sulfate proteoglycans and gC (HSV-1; Herold et al.,
1991) or gB (HSV-2; Cheshenko and Herold, 2002) and
engagement of herpes virus entry mediator coreceptors by
Figure 8. Viruses deleted in gL or gD fail to induce 
a Ca
2  response. Fura-loaded Vero cells were 
exposed to gL86 (A and B) or KOSgD  (C and D) 
purified from complementing (left) or noncomple-
menting (right) Vero cells, and the [Ca
2 ]i (nM) 
response was monitored. (E) Results from a single 
experiment in which 3–7 cells were monitored are 
shown, and the mean   [Ca
2 ]i obtained from two 
independent experiments is depicted graphically. 
Results are the mean   SD obtained from three 
independent experiments; asterisks indicate 
P   0.001, ANOVA.T
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gD (Spear et al., 2000), we propose that a signal is trans-
duced, which may activate phosphoinositide-specific PLC .
PLC  catalyzes the hydrolysis of phosphatidylinositol 4,5-
bisphosphate to IP3. IP3 diffuses through the cytosol, binds
to an IP3-sensitive receptor, and opens Ca
2  channels in the
membrane of the ER, releasing Ca
2  into the cytosol. The
release of ER Ca
2  stores, in turn, may promote opening of
Ca
2  channels at the plasma membrane, as suggested by the
shoulder in the Ca
2  response and the finding that pretreat-
ment with nifedipine and verapamil results in a loss of this
shoulder. Release of IP3-sensitive stores, but not the influx of
Ca
2  across the plasma membrane, is important for HSV in-
fection as indicated by the inhibitory effects of 2-APB (but
not verapamil and nifedipine) on transport of VP16 to the
nucleus, expression of ICP4, and plaque formation. This is
further supported by the finding that chelation of intracellu-
lar Ca
2  with BAPTA-AM prevents VP16 transport and
ICP4 expression. Possibly, the increase in [Ca
2 ]i facilitates
membrane fusion between the HSV envelope and cell
plasma membrane. Alternatively, the signaling pathway may
be important for delivery of viral capsids to the cytoplasm or
to their nuclear transport.
HSV invasion also triggers phosphorylation of FAK. This
response occurs within 5–10 min after exposure to virus and
could be triggered directly by the increases in [Ca
2 ]i or in
response to viral entry. The notion that FAK phosphoryla-
tion is linked to the Ca
2  response is supported by the find-
ing that treatment of cells with 2-APB or BAPTA-AM re-
duced subsequent FAK phosphorylation. Phosphorylation
of FAK promotes reorganization of the actin cytoskeleton, a
process that may be important in nuclear trafficking of inter-
nalized virus. Microtubules have been shown to play a role
in transport of the HSV viral capsid to the cell nucleus, al-
though the role of FAK was not evaluated (Sodeik et al.,
1997). Notably, phosphorylation of FAK and related cyto-
skeletal proteins has also been shown to be important in
HIV and adenoviral invasion. Binding of HIV gp120 to
CD4 and chemokine coreceptors induces phosphorylation
and intracellular association of FAK and CCR5 (Cicala et
al., 1999). Adenoviral internalization is associated with
phosphorylation of FAK and p130cas (Li et al., 2000).
Our analyses suggest that binding of virus to heparan sul-
fate proteoglycan receptors and engagement of gD corecep-
tors are not sufficient to trigger the cellular signaling path-
ways. Similarly, interactions between gH–gL and the cell, in
the absence of gD or gB, is not adequate. This follows from
the observations that viruses deleted in gB, gD, or gL fail to
induce the signaling events. In contrast, HI virus, which re-
tains the ability to enter cells, induces FAK phosphorylation.
The requirement for the full complement of essential glyco-
proteins (gB, gD, and gH–gL) to trigger the signaling events
suggests that the pathway is activated in response to initiation
of the fusion process or subsequent early events in invasion.
These results differ from those obtained with the related
 -herpes virus, HCMV. Activation of a cellular receptor for
HCMV gH–gL (a 92.5-kD cellular protein) directly or indi-
rectly by anti-idiotypic antibodies mediates transmembrane
signaling events resulting in increases in [Ca
2 ]i (Keay et al.,
1995; Milne et al., 1998; Baldwin et al., 2000). No cellular
Figure 9. Viral penetration is required for FAK phosphorylation. 
Serum-starved CaSki cells were mock infected or exposed to 
HSV-1(KOS)gL86, HSV-1(KOS) gD , or HSV-2(g)gB-2
  grown on 
complementing ( ) or noncomplementing ( ) cells as indicated 
or exposed to HSV-2 (G) or HI-HSV-2 (HI) virus and FAK phosphor-
ylation monitored by preparing cell lysates 10 min after citrate 
treatment. Blots were probed with anti-FAK pY
397 and then stripped 
and reprobed with mAb to total FAK. Gels are representative of at 
least two independent experiments.
Figure 10. Model of HSV entry. See Discussion for description.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
C
e
l
l
 
B
i
o
l
o
g
y
Ca
2  signaling and HSV entry | Cheshenko et al. 291
receptor for the gH–gL complex of HSV-1 or HSV-2 has yet
been identified. Possibly, the gH–gL complex for HSV (in
the presence of gB and gD) also engages a cellular receptor
that directly or indirectly activates PLC . Recent experi-
ments have shown that phosphoinositide-specific PLC  may
be activated by phosphatidylinositol-3-kinase, which can act
upstream of PLC  (Bierne et al., 2000).
In summary, these analyses demonstrate that Ca
2  signal-
ing pathways play a key role in facilitating early events in
HSV-1 and HSV-2 invasion. Because the signaling re-
sponses occur within minutes after exposure to virus, it
seems likely that they are associated with fusion of the viral
envelope and cell membrane and/or an immediate post-
entry event. Activation and release of IP3-sensitive Ca
2  stores
and subsequent phosphorylation of FAK are dependent on
the presence of the full complement of essential envelope
glycoproteins. Defining the specific cellular pathways acti-
vated during HSV entry and precisely how the virus triggers
these pathways is key to understanding the process of viral
invasion, and should facilitate development of novel strate-
gies to prevent HSV entry and infection.
Materials and methods
Cells and viruses
Vero (monkey kidney epithelial) and CaSki (human cervical epithelial)
cells were obtained from the American Type Culture Collection and
passed in Dulbecco’s modified essential medium (DMEM) supplemented
with 10% FBS. The cell lines 79VB4 and VD60 (provided by P. Spear,
Northwestern University, Evanston, IL) and VgB2 are gL-, gD-, and gB-2–
expressing Vero cell lines, respectively. These cell lines were passed in
DMEM supplemented with 10% FBS. The 79VB4 cells were grown in the
presence of 200  g/ml G418 sulfate (Montgomery et al., 1996) and the
VgB2 cell line in the presence of 500  g/ml G418 sulfate (Cheshenko and
Herold, 2002). The wild-type viruses HSV-1(KOS) (provided by P. Spear),
HSV-2(G) (provided by B. Roizman, University of Chicago, Chicago, IL),
and VSV-Indiana (provided by P. Palese, Mount Sinai School of Medicine,
New York, NY) were grown on Vero cells. HI virus was prepared by heat-
ing to 56 C for 1 h (Moriuchi et al., 2000). HSV-1 (KOS)(gL86), a mutant in
which the Escherichia coli  -galactosidase gene replaces part of the gL
ORF, was grown on 79VB4 cells or Vero cells as indicated (Montgomery et
al., 1996; Qie et al., 1999). HSV-1(KOS)gD , a mutant in which the E. coli
 -galactosidase gene replaces part of the gD ORF, was grown on VD60 or
Vero cells as indicated (Dean et al., 1994). HSV-2(G)gB-2
 , a mutant in
which the hygromycin/enhanced green fluorescent fusion protein replaces
part of the gB-2 ORF, was grown on VgB-2 or Vero cells as indicated
(Cheshenko and Herold, 2002).
Purification and quantification of viruses
Viruses were purified from Vero or complementing cells on dextran gradi-
ents as described previously (Herold et al., 1991, 1994). Titers of the puri-
fied virus were determined by plaque assays. Relative viral particle num-
bers were determined by comparing the amounts of gB or gD by optical
densitometry after Western blotting with mAb 1123 (anti-gB) or mAb1103
(anti-gD) (Goodwin Institute, Plantation, FL), as described previously (Tal-
Singer et al., 1995; Qie et al., 1999; Cheshenko and Herold, 2002).
Reagents
Verapamil, nifedipine, 2-APB, Tg, EGTA, EGTA-AM, and ionomycin were
purchased from Calbiochem and diluted in DMSO or PBS per manufac-
turer’s instructions. The acetoxymethyl ester of Fura-2 (Fura-2/AM) and the
cell-permeable cytosolic Ca
2  chelator, BAPTA-AM, were purchased from
Molecular Probes, Inc. Heparin was purchased from Sigma-Aldrich.
Measurement of [Ca
2 ]i
Cells were loaded with 25  M Fura-2/AM prepared in PBS for 30–60 min,
rinsed with PBS for 30 min at 37 C, and then exposed sequentially to
buffer or pharmacological inhibitors and purified HSV diluted in PBS at
37 C. The viral inoculum was equivalent to an moi equal to 1–5 pfu/cell
(based on titer on complementing cells) or an equivalent number of viral
particles for noninfectious virus. Using an inverted epifluorescence micro-
scope (Eclipse TE300; Nikon) linked to a cooled CCD camera (Pentamax;
Princeton Instruments) interfaced with a digital imaging system (MetaFluor;
Universal Imaging Corp.), [Ca
2 ]i was measured in individually identified
Fura-2–loaded cells visualized using an S Fluor 40  objective (NA 0.9,
WD 0.3; Nikon) as described previously (Woda et al., 2002). Cells were
alternately excited at 340 and 380 nm, and the images were digitized for
subsequent analysis. Images were acquired every 2–10 s. An intracellular
calibration was performed at the conclusion of each experiment according
to previously described techniques (Grynkiewicz et al., 1985; Woda et al.,
2002). The 340/380-nm fluorescence ratio was determined initially in the
presence of a Ca
2 -free bath plus 10  M EGTA-AM (Rmin), and then in a
2-mM Ca
2  bath containing 10  M ionomycin (Rmax). The equation used to
calculate experimental values of [Ca
2 ]i was: [Kd(R Rmin)/Rmax R)](Sf2/Sb2),
where R is the observed ratio of emitted light, Kd is the dissociation con-
stant for Fura-2 and Ca
2  (assumed to be 224 nM), and Sf2 and Sb2 are the
fluorescence signals of free and bound dye at 380 nm, respectively (Gryn-
kiewicz et al., 1985). 7–15 cells were monitored for each experiment.
Plaque assays
Synchronized plaque assays in which pharmacological inhibitors were
added during viral penetration were conducted as described previously
(Herold et al., 2002). In brief, cells in 6-well dishes were precooled and
exposed to HSV or VSV at 4 C for 2 h to allow binding. The moi was se-
lected to yield  200–500 pfu/well (e.g., moi  0.005 pfu/cell) on control
wells. Unbound virus was removed and the cells were washed three times
with PBS and then treated with 10  M verapamil or nifedipine, 100  M
2-APB, 10  M Tg, or buffer (DMSO or PBS). Cells were immediately trans-
ferred to 37 C to allow viral penetration for 1 h. Unpenetrated virus was
inactivated by washing the cell monolayer with a low pH citrate buffer (50
mM sodium citrate and 4 mM KCl, adjusted to pH 3.0) for 2 min, and then
by washing three times with PBS. The cells were then overlaid with me-
dium containing 0.5% methylcellulose for 48 h. For HSV-1(KOS) and
HSV-2(G), plaques were counted by immunoassay (black-plaque; Herold
et al., 1991). For VSV, cells were overlaid with 0.1% methylcellulose,
fixed after 24 h with methanol, and stained with Giemsa.
VP16 and ICP4 time-course assays
To examine which steps in HSV infection are inhibited by the pharmaco-
logical agents, the time of introduction of the drug was varied and infec-
tion was monitored by examining transport of the tegument protein VP16
to the nucleus or expression of immediate early gene product, ICP4. Syn-
chronized infectivity assays were conducted as described above, except
the moi was equivalent to 1 pfu/cell and the penetration time (time from
temperature shift to citrate treatment) was reduced to 15 min. The pharma-
cological agents or control buffers were added during the 4 C binding pe-
riod, at the time the cells were transferred to 37 C (penetration), or imme-
diately after the citrate treatment for 1 h. The cells were then overlaid with
medium and viral infection was monitored by examining transport of VP16
or expression of ICP4 as described below.
To examine transport of VP16 to the nucleus, nuclear extracts were pre-
pared 4 h after infection as described previously (Melchjorsen et al., 2002).
The nuclear proteins were separated on an 8.5% SDS-polyacrylamide gel
and transferred to a PVDF membrane (PerkinElmer) using a Trans-Blot sys-
tem (Bio-Rad Laboratories) and blocked overnight in 5% milk-TBS. Mem-
branes were incubated with mouse anti-VP16 (1:500; Santa Cruz Biotech-
nology, Inc.), diluted in 5% milk-TBS for 2 h, and rinsed extensively in
TBST (50 mM Tris-Cl, pH 7.4, 150 mM NaCl, and 0.05% Tween 20). The
membranes were then incubated with HRP-conjugated goat anti–mouse
IgG (1:1,000; Calbiochem) in 5% milk-PBS for 2 h. After rinsing, the mem-
branes were developed using the Western Lightning Chemiluminescence
Reagent Plus (PerkinElmer). Blots were scanned and analyzed using the
Gel Doc 2000 system (Bio-Rad Laboratories).
To examine ICP4 expression, infected cells were harvested 5 h after in-
fection in lysis buffer (1% SDS, 50 mM Tris-Cl, pH 7.4, 55 mM EDTA, and
I mM DTT), which was supplemented with complete protease inhibitors
(Roche). The supernatant (soluble fraction) and pellet (insoluble fraction)
were separated by centrifugation at 16,000 g at 4 C, and the protein con-
centrations in the supernatants were determined using the DC Protein As-
say (Bio-Rad Laboratories). The supernatants were suspended in SDS sam-
ple buffer (100 mM Tris-Cl, pH 6.8, 1%  -mercaptoethanol, 4% SDS,
0.2% bromophenol blue, and 20% glycerol) boiled for 4 min. The proteins
were separated on an 8.5% SDS-polyacrylamide gel and transferred to a
PVDF membrane (PerkinElmer) using a Trans-Blot system (Bio-Rad Labora-
tories) and blocked overnight in 5% milk-TBS. Membranes were incubatedT
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with mouse anti-ICP4 1101 (Goodwin Institute, Plantation, FL) or anti-
 -actin A5441 (Sigma-Aldrich) diluted in 5% milk-TBS for 2 h, then rinsed
extensively in TBST (50 mM Tris-Cl, pH 7.4, 150 mM NaCl, and 0.05%
Tween 20). The membranes were then incubated with HRP-conjugated
goat anti–mouse IgG (1:1,000; Calbiochem) in 5% milk-PBS for 2 h. After
rinsing, the membranes were developed using the Western Lightning
Chemiluminescence Reagent Plus (PerkinElmer). Blots were scanned and
analyzed using the Gel Doc 2000 system.
Detection of FAK phosphorylation by immunoblot
Nearly confluent CaSki or Vero monolayers were preincubated with se-
rum-free medium for 24 h before infection, and were then exposed to
HSV viruses at an moi of 10 pfu/cell for 5, 10, 20, or 30 min. Cell lysates
were prepared as described above. Proteins were separated by SDS-PAGE
and immunoblots prepared as described above. Membranes were incu-
bated with a 1:1,000 dilution of rabbit anti-FAK[pY
397], which recognizes
the autophosphorylation site of FAK (Biosource International). The mem-
branes were then stripped and reincubated with a 1:1,000 dilution of
mouse anti-FAK mAb (F-15020; Transduction Laboratories), which recog-
nizes total FAK.
Effects of BAPTA-AM or EGTA on viral infection 
and FAK phosphorylation
CaSki or Vero cells were pretreated for 2 h at 37 C with 10 or 50  M
BAPTA-AM or with 0.5 mM EGTA, washed three times, and exposed to
HSV or VSV as described above. Infection was monitored using plaque as-
says, transport of VP16 to the nucleus, or expression of ICP4. To examine
the effects of the chelators on FAK phosphorylation, cells were serum
starved for 24 h, treated with the chelators for 2 h, and then infected. At
various times after infection, cell lysates were prepared as described
above. Proteins were separated by SDS-PAGE and immunoblots were in-
cubated with antibodies directed against FAK[pY
397] or ICP4.
Cell viability assay
The effects of the pharmacological agents on cell viability were deter-
mined by the metabolic reduction of the tetrazolium salt MTS (CellTiter
96
®; Promega). Half-confluent Vero or CaSki cells were exposed to various
concentrations of each drug for the indicated times, washed three times,
and overlaid with fresh medium. Cell viability was examined at 24 h. Con-
trols included cells exposed to media in the absence of any drugs and cells
exposed to 0.1% nonoxynol-9 (Sigma-Aldrich), a detergent cytotoxic to
cells in culture (Herold et al., 1999).
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